Foundation News

GBS|CIDP Foundation International announces the first recipient of the Benson Fellowship to fund a Peripheral Inflammatory Neuropathy Fellowship

NARBERTH, Pa., Nov. 11, 2014 /PRNewswire/ — The GBS|CIDP Foundation International has announced the recipient of the first Benson Fellowship. This year’s winner is Dr. Ruth Huizinga, from Rotterdam, The Netherlands. Ruth presented her project, “High innate responsiveness to microbial triggers predisposing to the Guillain- Barre’ syndrome: identification of genetic causal variants” at the Foundation’s 13th International…

GBS/CIDP Foundation International announces the establishment of the Benson Fellowship

NARBERTH, PA, November 8, 2013 /PRNewswire/ – The GBS/CIDP Foundation International has established the Benson Fellowship to fund Peripheral Neuropathy Fellowships in honor of Robert Benson, a survivor of Guillain-Barre’ Syndrome, and his wife Estelle Benson. The Foundation voted to endow over $1,600,000 of its financial resources to initially fund the Fellowship. The purpose of the Benson…

Save the Date: 13th International Symposium

Dates: October 31st – November 2nd, 2014 Location: Walt Disney World Coronado Springs Resort and Convention Center in Lake Buena Vista, Florida Find out more now! Workshops, “Ask the Expert”, Research Updates, Networking with Members, “Walk & Roll” and much more. Free Airport Transportation on Walt Disney World Express Free WIFI on the hotel property Room Rate $125…

Campaign to Raise Awareness of Rare Neurological Condition

Neuropathy Action Foundation and GBS/CIDP Foundation International Launch Multifocal Motor Neuropathy (MMN) Campaign to Raise Awareness of Rare Neurological Condition Educational Brochure and Public Service Announcement Intended to Help with Early and Accurate Diagnosis of Serious Condition FOR IMMEDIATE RELEASE, August 15, 2013, Santa Ana, CA — The Neuropathy Action Foundation (NAF) and the GBS/CIDP…

To All Those With Chronic Inflammatory Demyelinating Polyneuropathy

Recently, one of the physicians on the GBS/CIDP Foundation Medical Advisory Board saw a man who carried the diagnosis of CIDP for 2 years. During that time, he received IVIg monthly for 18 months then plasmapheresis monthly for five months without any clinical improvement. He went to a GBS/CIDP Foundation Center of Excellence where it…

Privigen Shows Improved Function for CIDP Patient

CSL Behring reports that data presented from the Privigen Impact on Mobility and Autonomy (PRIMA) trial at the Peripheral Nerve Society Inflammatory Neuropathy Consortium Meeting in Rotterdam, Netherlands, suggests that treatment with Privigen®, an intravenous immunoglobulin (IVIg), may lead to improvement in function in CIDP patients. Click here to learn more.

Pagination